博瑞医药: 关于不提前赎回“博瑞转债”的公告

Core Viewpoint - The company has decided not to exercise the early redemption rights of its convertible bonds, despite triggering the conditional redemption clause due to stock price performance [1][6]. Group 1: Conditional Redemption Trigger - From April 28, 2025, to May 21, 2025, the company's stock price met the condition of closing at or above 130% of the conversion price for 15 out of 30 trading days, triggering the conditional redemption clause [1][5]. - The conversion price for the bonds is set at 45.29 CNY per share [5]. Group 2: Decision on Early Redemption - On May 21, 2025, the company's board of directors held a meeting and approved the decision not to redeem the "BoRui Convertible Bonds" early, considering various factors including operational performance and market conditions [6]. - The company will reassess the situation after August 22, 2025, to determine if the redemption clause is triggered again [2][6]. Group 3: Convertible Bond Issuance Overview - The company issued 4.65 million convertible bonds with a total value of 465 million CNY, with a maturity period of six years starting from January 4, 2022 [2]. - The bonds were listed on the Shanghai Stock Exchange on January 27, 2022, under the name "BoRui Convertible Bonds" [2]. Group 4: Conversion Price Adjustments - The conversion price has been adjusted multiple times due to annual profit distributions, with the latest adjustment occurring on June 2023 [3][4].